Fundz

Masimo Corporation

Irvine, California, United States · Audio, Biotechnology, Consumer Electronics

Masimo Corporation is a medical technology company that develops, manufactures, and markets non-invasive patient monitoring technologies, hospital automation solutions, and connectivity products.

Key facts

Headquarters
Irvine, California, United States
Employees
3,436
Industries
Audio, Biotechnology, Consumer Electronics
Website
www.masimo.com
LinkedIn
Company page

Recent activity at Masimo Corporation

  • : Masimo Appoints Tim Benner as President
  • : SEC 8-K (5.02): On June 9, 2026, the Company reported the resignation of six directors, including Catherine Szyman, Michelle Brennan, Quentin Koffey, Wendy Lane, Tim Scannell, and Darlene Solomon, effective following the merger. Frank McFaden was appointed as the director of the Surviving Corporation. Additionally, the Company entered into Separation and Consulting Agreements with Catherine Szyman, Gregory Meehan, and Charles Dadswell, allowing them to resign their employment while providing consulting services for three months following the merger at a fee based on their prior salaries. The Executives are also entitled to change-in-control severance benefits as per their previous arrangements. This restructuring is a result of the corporate merger, indicating significant changes in corporate governance and management.
  • : SEC 8-K (7.01): On May 4, 2026, the Company disclosed the results of its Special Meeting through a press release. This filing serves as a Regulation FD disclosure under Item 7.01. The press release includes forward-looking statements regarding the expected timing and potential effects of an upcoming Merger. Key risks associated with the Merger are mentioned, including uncertainties regarding completion, regulatory approvals, and potential impacts on business operations and personnel retention. The announcement is critical for shareholders as it outlines the expectations for the merger and its implications.
  • : SEC 8-K (8.01):
  • : SEC 8-K (1.01): On February 16, 2026, Masimo Corporation entered into a Material Definitive Agreement in the form of a Merger Agreement with Danaher Corporation and its subsidiary, Mobius Merger Sub, Inc. Under the terms of the agreement, Mobius Merger Sub will merge with Masimo Corporation, which will continue as a wholly owned subsidiary of Danaher Corporation. Shareholders of Masimo will receive $180.00 in cash per share, with specific treatment for options and restricted stock units. This merger represents a significant transaction aimed at consolidating operations and enhancing market capabilities for Danaher Corporation, with immediate effects on Masimo's outstanding equity awards.
  • : SEC 8-K (1.01): On February 16, 2026, Masimo Corporation entered into a Merger Agreement with Danaher Corporation and Mobius Merger Sub, Inc. Under the agreement, Mobius Merger Sub will merge with Masimo Corporation, with Masimo continuing as a wholly owned subsidiary of Danaher. Additionally, a Voting and Support Agreement was signed with Politan Capital Management LP, wherein Politan agrees to vote in favor of the Merger Agreement. This strategic move is poised to enhance operational synergies and expand market reach, marking a significant corporate development.
  • : SEC 8-K (7.01): The filing pertains to Regulation FD Disclosure under Item 7.01 regarding Masimo Corporation's participation in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. During the conference, the CEO and CFO will present select preliminary financial results for both the fourth quarter and full-year 2025. Additionally, supplemental financial information for fiscal 2025 is being made available to investors, which includes discussions on non-GAAP measures. The materials referenced are included as Exhibit 99.2, emphasizing the company's transparency regarding its financial performance and measures used to evaluate its results.
  • : SEC 8-K (7.01): On December 3, 2025, Masimo Corporation held its 2025 Investor Day, as announced in a press release dated the same day, included as Exhibit 99.1 in the filing. During the event, CEO Katie Szyman alongside other executives presented the company's financial guidance for fiscal year 2025 and shared long-range financial targets. A replay of the presentation is accessible on Masimo's website, and further details are available in Exhibit 99.2 of the report. This event is significant as it reaffirms Masimo's financial outlook amidst ongoing operational strategies.
  • : SEC 8-K (1.01): On December 1, 2025, Masimo Corporation entered into a new Credit Agreement providing for a total unsecured borrowing capacity of up to $1.4 billion, which consists of a $250 million Term Loan and $750 million in unsecured revolving commitments, along with an option to increase the borrowing capacity by an additional $400 million. This Credit Agreement replaces the previously existing Credit Agreement dated April 11, 2022, which was terminated as part of the refinancing process. The proceeds are intended to finance the Refinancing and pay associated fees, with future funds to be used for general corporate purposes, capital investments, and working capital needs. The Credit Facility includes provisions for letters of credit and is set to mature on December 1, 2030.
  • : SEC 8-K (1.02): On December 1, 2025, Masimo Corporation terminated its obligations under a Credit Agreement dated April 11, 2022, effectively paying off all amounts owed. This decision was made in conjunction with financial restructuring that involved multiple lenders and Citibank, N.A. serving as the administrative agent. The termination of this credit agreement marks a significant step in Masimo's financial strategy, potentially impacting their liquidity and capital management. This move could enable the company to optimize its financial structure moving forward.

Leadership

  • Tim Benner, President
  • Bilal Muhsin, Chief Operating Officer
  • Micah Young, Chief Financial Officer
  • Joe Kiani, Chief Executive Officer
  • Narii Peltzer, Finance Manager
  • Julie Nakata, Senior VP, Finance
  • Robert Maxwell, Director, Financial Planning
  • Duy Nguyen, Masimo Employee
  • William Chan, Principal Design Engineer
  • Shanta F., Marketing Director
  • Barry Hickerson, Director of Marketing
  • Maureen Turner, Sales

Verified email and direct lines for Masimo Corporation’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

Masimo Corporation files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Masimo Corporation in the news

Companies similar to Masimo Corporation

About Masimo Corporation: questions and answers

What does Masimo Corporation do?

Masimo Corporation is a medical technology company that develops, manufactures, and markets non-invasive patient monitoring technologies, hospital automation solutions, and connectivity products.

Where is Masimo Corporation headquartered?

Masimo Corporation is headquartered in Irvine, California, United States.

How many employees does Masimo Corporation have?

Masimo Corporation has about 3,436 employees.

Who leads Masimo Corporation?

Tim Benner is a President at Masimo Corporation.

What is the latest news on Masimo Corporation?

On Aug 03, 2026, Masimo Appoints Tim Benner as President

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Masimo Corporation across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.